期刊文献+

528例原发性肝细胞癌患者肝切除术后1年生存分析 被引量:12

Analysis on factors influencing one-year-survival of hepatocellular carcinoma patients after hepatectomy
原文传递
导出
摘要 目的探讨原发性肝细胞癌患者(hepatocellularcarcinoma,HCC)肝切除术后1年生存状况及影响因素。方法回顾性分析1997年1月至2008年12月因HCC行肝切除的528例患者术后1年生存结果和影响因素。结果本组患者随访期间死亡302例,患者1年累积生存率为84%。1年内死亡原因主要为HCC复发转移(78.1%,75/96)及与原发的肝病相关合并症(19.8%,19/96)。大肝癌(P=0.047)、血管癌栓(P=0.018)、组织学中低分化(P=0.001)和病理切缘肿瘤残留(P=0.004)者是HCC患者1年内HCC复发转移死亡的独立危险因素;伴有门静脉高压症(P=0.001)是预示术后肝病相关死亡的独立因素。非R0切除的患者是1年内死亡(占59.3%)最重要的因素。结论影响HCC切除术后1年生存的主要因素是HCC复发转移与原发的肝病相关因素,非R0切除是导致原发性HCC患者术后早期复发死亡的最主要的因素,术前伴有门静脉高压症是影响HCC患者术后肝病相关死亡的独立危险因素。 Objective To analyze the factors that influence the survival condition during the first year after hepatectomy in patients with hepatocellular carcinoma (HCC). Methods Five hundred twenty-eight HCC cases undergoing hepatectomy were included from January 1997 to December 2008. The factors and survival outcomes in these patients were analyzed. Results There were 302 patients dying during a medium follow-up of 35 months and 1-year cumulative survival was 85%. The causes of death during first year were tumor recurrence (78.1%, 75/96) and liver dyscompensation (19. 8%, 19/96). By Cox regression analysis, tumor size≥5 cm ( P = 0. 047 ), vascular invasion ( P = 0. 018 ), histologic moderately and poorly differentiation ( P = 0. 001 ) and pathologically positive margin ( P = 0. 004 ) were significantly associated with tumor recurrence, and portal hypertension was an independent factor for patients dying from liver dysfunction ( P = 0. 001 ). Positive tumor margin was the most important factor associated with postoperative death within one year (59.3%, 60/96). Conclusions During the first year after HCC resection, tumor recurrence and liver dysfunction are main factors influencing HCC patients' survival, non- R0 resection is the main factor causing tumor recurrence, and portal hypertension is an independent factor for patients dying of liver dyscompensation.
出处 《中华普通外科杂志》 CSCD 北大核心 2012年第2期92-95,共4页 Chinese Journal of General Surgery
关键词 肝细胞 肝切除术 肿瘤复发 局部 Carcinoma, hepatocellular Hepatectomy Neoplasm recurrence, local
  • 相关文献

参考文献5

  • 1赵平,孔灵芝.肝癌.//全国肿瘤防治研究办公室.中国肿瘤死亡报告--全国第三次死因回顾抽样调查.1版.北京:人民卫生出版社,2010:37.
  • 2Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg, 2006, 243: 229-235.
  • 3Shah SA, Greig PD, Gallinger S, et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coil Surg, 2006, 202:275-283.
  • 4黄帆,耿小平,刘付宝,赵红川,王国斌,赵义军.肝癌术后复发高危患者行TACE的意义[J].中华普通外科杂志,2010,25(6):490-492. 被引量:5
  • 5杨连粤,陈国栋.肝癌合并门静脉高压症的治疗选择[J].中国实用外科杂志,2009,29(5):387-389. 被引量:8

二级参考文献18

  • 1刘鹏飞,刘荣华,徐荷,吴孟超.原发性肝癌术后预防性TACE的意义(附433例病例随访)[J].中华肝胆外科杂志,2005,11(2):81-82. 被引量:52
  • 2杨连粤,刘振.门静脉高压症并上消化道出血的外科治疗进展[J].临床外科杂志,2007,15(3):162-163. 被引量:16
  • 3Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma[J].Lancet,2003,362(9399):1907-1917.
  • 4Minagawa M,Makuuehi M,Kakayama T,et al.Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus[J].Ann Surg,2001,233(3):379-384.
  • 5Ishizawa T,Hasegawa K,Aoki T,et al.Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocelluhr carcinoma[J].Gastroenterology,2008,134 (7):1908-1916.
  • 6Konishi M,Ryu M,Kinoshita T,et al.Surgical treatment of hepatocellular eareinoma with direct removal of the tumor thrombus in the main portal vein[J].Hepatogastroenterology,2001,48(41):1421-1424.
  • 7Sugawara Y,Yamamoto J,Shimada K,et al.Splenectomy in patients with hepatocellular carcinoma and hypersplenism[J].J Am Coll Surg,2000,190(4):446-450.
  • 8Lian-Yue Yang,Feng Fang,Di-Peng Ou,et al.Solitary huge hepatocellular carcinoma:a specific subtype,of hepatocellular carcinoma with good outcome,after hepatic resection[J].Ann Surg,2009,249(1):118-123.
  • 9Llovet JM,Bruix J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival.Hepatology,2003,37:429442.
  • 10Hsu C,Cheng JCH,Cheng AL,et al.Recent advances in non-surgical treatment for advanced hepatocellular carcinoma.J Formos Med Assoc,2004,103:483495.

共引文献12

同被引文献126

  • 1张万广,张必翔.肝细胞癌的分期与治疗策略[J].外科研究与新技术,2013,2(4):251-254. 被引量:4
  • 2吴育连,苏昆仑,董鑫,于俊秀,彭淑牖.肝癌切除术后早/晚期复发的危险因素与治疗[J].中华肝胆外科杂志,2006,12(6):370-373. 被引量:23
  • 3王华毅,张兆祥.脾酪氨酸激酶与肿瘤[J].癌症,2007,26(5):555-560. 被引量:7
  • 4李德志,蒲萍,李光辉.立体定向放射治疗腹腔转移癌的临床分析[J].中国肿瘤临床与康复,2007,14(4):326-328. 被引量:2
  • 5Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the study of the liver. J Hepatol, 2001, 35: 421-430.
  • 6Choi GH, Park JY, Hwang HK, et al. Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma. Liver Int, 2011,31:485-493.
  • 7Yang LY, Fang F, Ou DP, et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg, 2009, 249 : 118- 123.
  • 8Fujisaki S, Miyake H, Amano S, et al. Influence of the extent of hepatectomy on the portal hypertensive state in patients with hepatoma. Hepatogastroenterology, 1999,46:2490-2494.
  • 9Capussotti L, Ferrero A, Vigano L, et al. Portal hypertension: contraindication to liver surgery.'? World J Surg, 2006, 30 : 992- 999.
  • 10Sugawara Y, Yamamoto J, Shimada K, et al. Splenectomy in patients with hepatocellular carcinoma and hypersp|enism. J Am Coll Surg, 2000, 190:446-450.

引证文献12

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部